Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQ2K1V)

Drug Name
SCH-442416 Drug Info
Synonyms
316173-57-6; SCH 442416; SCH-442416; UNII-ZMC4G1W59S; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCH442416; ZMC4G1W59S; CHEMBL136689; SCH-442,416; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCHEMBL981184; GTPL3283; CTK8B9468; CHEBI:92814; DTXSID70443263; MolPort-023-276-442; ZINC602847; HMS3269G07; BCP01942; MFCD08703126; BDBM50094037; ANW-62570; AKOS016003924; SCH442,416; NCGC00159575-01; AJ-23684; AC-27414
Cross-matching ID
PubChem CID
10668061
ChEBI ID
CHEMBL136689
CAS Number
CAS 316173-57-6
TTD Drug ID
D02YQO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Sulfur metabolism 2.03 1.04e-2 9/10 (90%) SELENBP1;SQOR;PAPSS1;...
beta-Alanine metabolism 2.02 5.21e-3 25/30 (83.33%) ALDH3A2;ALDH2;ACOX1;...
Allograft rejection 1.96 1.39e-2 32/38 (84.21%) HLA-B;HLA-DPA1;HLA-DQA1;...
Graft-versus-host disease 1.95 1.30e-2 32/42 (76.19%) HLA-B;HLA-DPA1;HLA-DQA1;...
Valine, leucine and isoleucine degradation 1.95 1.04e-2 42/48 (87.5%) ALDH3A2;ALDH2;MCCC2;...
Mineral absorption 1.86 1.21e-2 48/60 (80%) STEAP1;ATP2B4;MT1X;...
Type I diabetes mellitus 1.83 1.49e-2 38/43 (88.37%) HLA-B;HLA-DPA1;HLA-DQA1;...
Histidine metabolism 1.83 1.56e-2 16/22 (72.73%) MAOA;ALDH3A2;ALDH2;...
Selenocompound metabolism 1.79 1.97e-2 11/17 (64.71%) PAPSS1;KYAT3;PAPSS2;...
Autoimmune thyroid disease 1.78 2.39e-2 46/53 (86.79%) HLA-B;HLA-DPA1;HLA-DQA1;...
Ascorbate and aldarate metabolism 1.74 3.12e-2 15/30 (50%) ALDH3A2;ALDH2;UGT2B17;...
NF-kappa B signaling pathway -2.00 0.00e+0 90/104 (86.54%) BTK;IRAK1;NFKBIA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H